Article Contents ::
- 1 The Brand Name AXEPTA Has Generic Salt :: ATOMOXETINE
- 2 AXEPTA Is From Company Intas Priced :: Rs. 64.5
- 3 AXEPTA have ATOMOXETINE is comes under Sub class Anti Psychotics of Main Class Nervous System
- 4 Main Medicine Class:: Nervous System Sub Medicine Class :: Anti Psychotics
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name AXEPTA Has Generic Salt :: ATOMOXETINE
AXEPTA Is From Company Intas Priced :: Rs. 64.5
AXEPTA have ATOMOXETINE is comes under Sub class Anti Psychotics of Main Class Nervous System
Main Medicine Class:: Nervous System Sub Medicine Class :: Anti Psychotics
Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
ATOMOXETINE | TAB | Rs. 64.5 | 10 |
Brand Name | Company / Manufacturers | Strength | Unit | Price / 10 |
AXEPTA | Intas | 18MG | 10 | Rs. 64.5 |
Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
From Intas :: AXEPTA | ATOMOXETINE | Nervous System | Anti Psychotics |
Indications for Drugs ::
Attention deficit hyperactivity disorder (ADHD)
Drug Dose ::
Oral Attention deficit hyperactivity disorder Adult: Initially, 40 mg/day may increase gradually after at least 7 days to 80 mg/day, up to 100 mg/day may be used after 2-4 wk. Child: >6 yr ?70 kg: Initially, 0.5 mg/kg/day, may increase gradually to approx 1.2 mg/kg/day. Max: 1.4 mg/kg or 100 mg, whichever is lower; >70 kg: Initially, 40 mg/day, may increase gradually after at least 7 days to 80 mg/day, up to100 mg/day may be used after 2-4 wk. Hepatic impairment: Moderate: Reduce dose by 50%. Severe: Reduce dose by 75%.
Contraindication ::
Angle-closure glaucoma. Not to be used with or within 14 days of discontinuing treatment with MAOIs.
Drug Precautions ::
Monitor height and wt gain especially during the initial period of treatment; dose reduction or treatment interruption may be needed in children whose growth or wt gain is not satisfactory. Patients with high BP or cardiovascular conditions that may be worsened by increases in BP or heart rate. Caution when used in patients with a history of psychotic illness or bipolar disorder. May increase the risk of urinary obstruction or hesitancy. Monitor for signs of clinical worsening, suicidality or unusual behavioural changes especially during the start of treatment and during dose changes. Safety and efficacy have not been established in patients <6 yr. Not recommended for use in pregnancy. Drug Side Effects ::
GI disturbances, anorexia and wt loss, fatigue. CNS symptoms e.g. headache, insomnia, sleep disturbances, dizziness, irritability and emotional lability. Cough, sinusitis or rhinorrhoea, urinary hesitancy or retention. Reduced libido and sexual dysfunction. Skin rashes, increased sweating and hot flushes.
Pregnancy category ::
3
Drug Mode of Action ::
Atomoxetine hydrochloride selectively inhibits noradrenaline reuptake w/ minimal affinity for other noradrenergic receptors or for other neurotransmitter receptors or transporters. It is used in the treatment of attention deficit hyperactivity disorder.
Drug Interactions ::
May cause additive effect when used w/ drugs that increase BP. May potentiate the effect of salbutamol on the CVS. May increase risk of cardiac events when used w/ drugs that affect cardiac conduction or electrolyte balance, or that inhibit CYP2D6 (e.g. fluoxetine, paroxetine, quinidine). Increased risk of QT prolongation w/ QT prolonging drugs (e.g. class Ia and III antiarrhythmics, moxifloxacin, erythromycin, TCAs, lithium, cisapride). Increased risk of seizures w/ drugs that are known to lower seizure threshold (e.g. phenothiazines, neuroleptics, mefloquine, bupropion, tramadol). Potentially Fatal: Increased neurotoxic effect w/ MAOIs.